| 000 | 01336 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250514002142.0 | ||
| 264 | 0 | _c20010712 | |
| 008 | 200107s 0 0 eng d | ||
| 022 | _a0277-3732 | ||
| 024 | 7 |
_a10.1097/00000421-200106000-00014 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHuntington, M O | |
| 245 | 0 | 0 |
_aTemporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance. _h[electronic resource] |
| 260 |
_bAmerican journal of clinical oncology _cJun 2001 |
||
| 300 |
_a279-82 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInsulin Resistance |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xmetabolism |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTopotecan _xpharmacology |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aKrell, K E | |
| 700 | 1 | _aArmour , W E | |
| 700 | 1 | _aLiljenquist, J E | |
| 773 | 0 |
_tAmerican journal of clinical oncology _gvol. 24 _gno. 3 _gp. 279-82 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00000421-200106000-00014 _zAvailable from publisher's website |
| 999 |
_c11334889 _d11334889 |
||